Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02435173 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy of CDZ173 in Patients With APDS/PASLI
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT02435173 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 37 participants.
The verdict
NCT02435173, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
This study was designed to explore CDZ173, a selective PI3Kδ inhibitor, in patients with genetically activated PI3Kδ, i.e., patients with Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency (APDS/PASLI). The study consisted of two parts: Part I was the open label part designed to establish the safety and pharmacokinetics of CDZ173 in the target population, as well as to select the optimal dose to be tested in Part II. Part II was designed to assess efficacy and safety of CDZ173 in the target population.
Interventions
- OTHER Placebo
- DRUG CDZ173
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2015-08-24 |
| Est. Completion | 2021-08-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02435173
The ClinicalTrials.gov registry entry for NCT02435173 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02435173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02435173 about?
NCT02435173 is a clinical study titled "Study of Efficacy of CDZ173 in Patients With APDS/PASLI". This study was designed to explore CDZ173, a selective PI3Kδ inhibitor, in patients with genetically activated PI3Kδ, i.e., patients with Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency (APDS/PASLI). The s...
What is the current status of trial NCT02435173?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2015-08-24. Estimated completion is 2021-08-16.
What interventions are being tested in trial NCT02435173?
The interventions under investigation include: Placebo (OTHER), CDZ173 (DRUG).
Who is sponsoring clinical trial NCT02435173?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.